The inhibition of FAK functionality by small molecules reduced both the motility and viability of cancer cells in both mouse models and human clinical trials [15–17], suggesting that FAK might be a potential therapeutic target to treat highly invasive types of cancers. Here, PTK2 is linked to cancer.